Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from groupe d'investigateurs nationaux pour l'etude des cancers ovariens (GINECO)

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 346-352

  Lortholary, A ^a   Largillier, R ^b   Weber, B ^c   Gladieff, L ^d   Alexandre, J ^e   Durando, X ^f   Slama, B ^g   Dauba, J ^h   Paraiso, D ⁱ   Pujade Lauraine, E ^e  

^a Centre Catherine de Sienne   (France)

^b Centre Azuréen Cancérologie   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CENTRE JEAN PERRIN   (France)

^g CENTRE HOSPITALIER D AVIGNON   (France)

^h Mont de Marsan Hospital   (France)

ⁱ Centre Hospitalier de l'Agglomeration Montargoise   (France)

Author keywords

Carboplatin; Chemotherapy; Platinum resistant; Recurrent ovarian cancer; Weekly paclitaxel; Weekly topotecan

Indexed keywords

CARBOPLATIN; PACLITAXEL; TOPOTECAN;

ADULT; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESISTANT RECURRENT OVARIAN CANCER; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84856331988     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr149     Document Type: Article

References (37)

1. Pujade-Lauraine E, Paraiso D, Cure H et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002; 21: 208a (Abstr 829).
2. Cree IA, Kurbacher CM, Lamont A et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007; 18: 1093-1101.
3. Bolis G, Parazzini F, Scarfone G et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1999; 72: 60-64.
4. Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel. in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18: 1193-1202.
5. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-1753.
6. Le T, Hopkins L, Baines KA et al. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol 2006; 102: 49-53.
7. Gynecologic Oncology Group, Markman M, Blessing J et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 436-440.
8. Dunder I, Berker B, Atabekoglu C et al. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur J Gynaecol Oncol 2005; 26: 79-82.
9. Kita T, Kikuchi Y, Takano M et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 2004; 92: 813-818.
10. Ghamande S, Lele S, Marchetti D et al. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003; 13: 142-147.
11. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002; 20: 2365-2369.
12. Buda A, Floriani I, Rossi R et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 2004; 90: 2112-2117.
13. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
14. Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 2005; 16: 749-755.
15. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
16. Torri V, Floriani I, Tinazzi A et al. Randomized trial comparing paclitaxel+ doxorubicin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy. Proc Am Soc Clin Oncol 2000; 19: 381a (Abstr 1506).
17. Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; 26: 3176-3182.
18. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
19. Pujade-Lauraine E, Paraiso D, Joly F et al. Is there a role for platinum in the treatment of patients with "platinum-resistant" relapsed advanced ovarian cancer (AOC)? A GINECO study. Proc Am Soc Clin Oncol 2003; 22: 451 (Abstr 1811).
20. Swisher EM, Mutch DG, Rader JS et al. Topotecan in platinum- and paclitaxelresistant ovarian cancer. Gynecol Oncol 1997; 66: 480-486.
21. Rose PG, Gordon NH, Fusco N et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000; 78: 228-234.
22. ten Bokkel Huinink W, Lane SR, Ross GA et al. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100-103.
23. Herzog TJ, Sill MW, Walker JL et al. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 2011; 120: 454-458.
24. Sehouli J, Stengel D, Harter P et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011; 29: 242-248.
25. Homesley HD, Benigno BB, Williams JA Jr, Vaccarello L. Weekly topotecan combined with weekly paclitaxel in second- or third-line therapy of epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 2001; 20: (Abstr 2516).
26. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
27. Vergote I, Rustin GJ, Eisenhauer EA et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000; 92: 1534-1535.
28. Rustin GJS, Nelstrop AE, Bentzen SM et al. Selection of active drugs for ovarian cancer based on CA 125 and standard response rates to phase II trials. J Clin Oncol 2000; 18: 1733-1739.
29. O'Byrne KJ, Bliss P, Graham JD et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated taxane nai{dotless}̈ve relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002; 21: 203a. (Abstr 808).
30. Kristensen G, Kaern J, Baekelandt M et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study. J Clin Oncol 2008; 26 (Suppl): 295s (Abstr 5508).
31. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
32. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinumresistant ovarian cancer. J Clin Oncol 2007; 25: 2811-2818.
33. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26: 890-896.
34. O'Boyle J, Lin WM, Coleman R et al. Combined carboplatin (C) and weekly paclitaxel (P) chemotherapy for recurrent gynecologic malignancies: preliminary data. Proc Am Soc Clin Oncol 2000; 19: 411a (Abstr 1623D).
35. Van der Burg ME, Vergote I, Burger CW et al. Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. J Clin Oncol 2004; 22 (Suppl) 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 463s (Abstr 5058).
36. Stathopoulos GP, Malamos NA, Aravantinos G et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 2007; 60: 123-128.
37. Rose PG, Smrekar M, Fusco N. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 2005; 96: 296-300.